Which antibiotics should be avoided in the management of uncomplicated pharyngitis?

Azithromycin Should Be Avoided in Pharyngitis Treatment

Azithromycin and clarithromycin should be avoided as first-line antibiotics for pharyngitis due to documented resistance patterns, inferior bacterial eradication rates, higher recurrence rates, and increased adverse events compared to penicillin. 1, 2, 3

Antibiotics to Avoid

Macrolides (Primary Concern)

• Azithromycin demonstrates:

  • Inferior early bacterial eradication compared to penicillin (OR 0.53) 2
  • Significantly worse late bacterial eradication (OR 0.38) 2
  • Higher late recurrence rates 2
  • Increased adverse events, particularly in children (OR 2.67 vs amoxicillin) 2, 3
  • Well-documented geographic and temporal resistance 1

• Clarithromycin shares similar resistance concerns with azithromycin 1, 4

Broad-Spectrum Antibiotics (General Principle)

The IDSA guidelines explicitly note that broad-spectrum antibiotics continue to be inappropriately prescribed despite lack of benefit 1. The evidence emphasizes that antimicrobial therapy provides no proven benefit for non-GAS pharyngitis, making broad-spectrum coverage unnecessary and harmful from an antimicrobial stewardship perspective.

Clinical Reasoning

The 2012 IDSA guidelines clearly state that macrolides (azithromycin, clarithromycin) have "well-known resistance that varies geographically and temporally" 1. This is reinforced by the most recent 2026 network meta-analysis showing azithromycin's inferior performance across multiple efficacy outcomes 2. A 2023 observational study from Palestine documented that azithromycin was the most commonly prescribed antibiotic (41.3%) despite being inappropriate—highlighting a widespread problem of nonadherence to guidelines 5.

Common Pitfall

The most significant error is prescribing azithromycin for its convenient 5-day dosing schedule. While the shorter course appears attractive for compliance, this convenience is negated by inferior bacterial eradication, higher recurrence rates, and contribution to macrolide resistance 2, 3. The 2023 Cochrane review confirms no clinically relevant advantage of macrolides over penicillin 3.

What Should Be Used Instead

First-line therapy remains:

• Penicillin V or amoxicillin for 10 days (strong, high-quality evidence) 1
• For penicillin-allergic patients (non-anaphylactic): First-generation cephalosporins (cephalexin, cefadroxil) for 10 days 1
• For true penicillin allergy: Clindamycin for 10 days is preferred over macrolides 1

The evidence consistently supports that penicillin remains the optimal choice due to narrow spectrum, low cost, absence of resistance, and proven efficacy in preventing complications including acute rheumatic fever 1, 3, 4.